Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Receives Average “Buy” Rating from Analysts

Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Rating) has been assigned a consensus “Buy” recommendation by the eighteen rating companies that currently cover the company, MarketBeat reports. Three analysts rated the stock with a hold rating and nine assigned the company a buy rating. The 12-month average target price among analysts who have rated the stock over the past year is $206.47.

A number of analysts have recently commented on the company. Piper Sandler lowered its target price on Jazz Pharmaceuticals from $197.00 to $193.00 in a Thursday, May 5 research report. Cowen raised his price target on Jazz Pharmaceuticals from $200.00 to $225.00 in a Thursday, May 5 report. Cantor Fitzgerald reissued an “overweight” rating on Jazz Pharmaceuticals shares in a Wednesday, March 2 report. Royal Bank of Canada lowered its price target on Jazz Pharmaceuticals from $216.00 to $214.00 and set an “outperform” rating for the company in a Wednesday, March 2 report. Finally, StockNews.com upgraded Jazz Pharmaceuticals from a “hold” rating to a “buy” rating in a Tuesday, April 26 report.

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 10,772 shares of the company in a trade that took place on Monday, April 4. The shares were sold at an average price of $158.33, for a total transaction of $1,705,530.76. Following completion of the transaction, the CEO now owns 346,062 shares of the company, valued at $54,791,996.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available on the SEC’s website. Additionally, CAO Patricia Carr sold 1,067 shares of the company in a trade that took place on Monday, May 9. The shares were sold at an average price of $148.94, for a total transaction of $158,918.98. As a result of the sale, the chief accounting officer now directly owns 7,229 shares of the company, valued at approximately $1,076,687.26. The disclosure of this sale can be found here. In the past 90 days, insiders have sold 22,330 shares of the company valued at $3,483,255. Insiders of the company own 4.30% of the shares of the company.

A number of large investors have recently bought and sold shares of JAZZ. Morgan Stanley increased its position in Jazz Pharmaceuticals by 81.1% in the second quarter. Morgan Stanley now owns 500,359 shares of the specialty pharmaceutical company worth $88,884,000 after purchasing an additional 224,068 shares during the period. Allianz Asset Management GmbH increased its stake in shares of Jazz Pharmaceuticals by 140.9% during the third quarter. Allianz Asset Management GmbH now owns 11,076 shares of the specialty pharmaceutical company worth $1,442,000 after acquiring 6,478 additional shares in the last quarter. First Republic Investment Management Inc. increased its stake in shares of Jazz Pharmaceuticals by 5.9% during the third quarter. First Republic Investment Management Inc. now owns 9,880 shares of the specialty pharmaceutical company worth $1,286,000 after acquiring 550 additional shares in the last quarter. Oppenheimer Asset Management Inc. increased its stake in shares of Jazz Pharmaceuticals by 1.4% during the third quarter. Oppenheimer Asset Management Inc. now owns 5,746 shares of the specialty pharmaceutical company valued at $748,000 after buying 81 additional shares last quarter. Finally, The Manufacturers Life Insurance Company increased its stake in the shares of Jazz Pharmaceuticals by 7.1% during the third quarter. The Manufacturers Life Insurance Company now owns 69,167 shares of the specialty pharmaceutical company valued at $9,006,000 after buying an additional 4,592 shares last quarter. 93.23% of the shares are held by institutional investors and hedge funds.

Shares of JAZZ opened at $150.91 on Friday. The company has a market capitalization of $9.40 billion, a PE ratio of -20.09, a PEG ratio of 1.24 and a beta of 0.79. Jazz Pharmaceuticals has a 12-month low of $117.64 and a 12-month high of $189.00. The stock’s 50-day moving average price is $156.91 and its two-hundred-day moving average price is $143.80. The company has a current ratio of 3.39, a quick ratio of 2.06 and a debt ratio of 1.66.

Jazz Pharmaceuticals Inc (NASDAQ:JAZZ – Get Rating) last released quarterly earnings data on Wednesday, May 4. The specialty pharmaceutical company reported earnings per share of $3.13 for the quarter, beating the consensus estimate of $3.00 by $0.13. Jazz Pharmaceuticals posted a positive return on equity of 22.45% and a negative net margin of 13.63%. The company posted revenue of $813.72 million in the quarter, versus analyst estimates of $853.73 million. During the same period last year, the company posted EPS of $3.42. The company’s quarterly revenue increased 33.9% year over year. Equity research analysts expect Jazz Pharmaceuticals to post EPS of 14.73 for the current fiscal year.

About Jazz Pharmaceuticals (Get an evaluation)

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops and markets pharmaceutical products for a variety of unmet medical needs in the United States, Europe and globally. The Company has a portfolio of products and product candidates focused on areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.

Read more

Get news and reviews for Jazz Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.